361 related articles for article (PubMed ID: 24580813)
41. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
42. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
[TBL] [Abstract][Full Text] [Related]
43. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
[TBL] [Abstract][Full Text] [Related]
44. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Baeten JM; Haberer JE; Liu AY; Sista N
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
[TBL] [Abstract][Full Text] [Related]
45. Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming.
Hillis A; Germain J; Hope V; McVeigh J; Van Hout MC
AIDS Behav; 2020 Nov; 24(11):3056-3070. PubMed ID: 32274670
[TBL] [Abstract][Full Text] [Related]
46. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
[TBL] [Abstract][Full Text] [Related]
47. Maximizing the Benefits of HIV Preexposure Prophylaxis.
Buchbinder SP
Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
[TBL] [Abstract][Full Text] [Related]
48. Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention.
Drain PK; Bardon AR; Simoni JM; Cressey TR; Anderson P; Sevenler D; Olanrewaju AO; Gandhi M; Celum C
Curr HIV/AIDS Rep; 2020 Oct; 17(5):487-498. PubMed ID: 32627120
[TBL] [Abstract][Full Text] [Related]
49. Pre-Exposure Prophylaxis Interventions among Black Sexual Minority Men: A Systematic Literature Review.
Turpin RE; Hawthorne DJ; Rosario AD
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206120
[TBL] [Abstract][Full Text] [Related]
50. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
[TBL] [Abstract][Full Text] [Related]
51. Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research.
Irungu E; Khoza N; Velloza J
Curr HIV/AIDS Rep; 2021 Dec; 18(6):490-499. PubMed ID: 34719745
[TBL] [Abstract][Full Text] [Related]
52. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
[TBL] [Abstract][Full Text] [Related]
53. Female and younger subjects have lower adherence in PrEP trials: a meta-analysis with implications for the uptake of PrEP service to prevent HIV.
Yun K; Xu JJ; Zhang J; Li JM; Hu QH; Chu ZX; Jiang YJ; Geng WQ; Shang H; Wang N
Sex Transm Infect; 2018 May; 94(3):163-168. PubMed ID: 28756409
[TBL] [Abstract][Full Text] [Related]
54. Improving Delivery and Use of HIV Pre-Exposure Prophylaxis in the US: A Systematic Review of Implementation Strategies and Adjunctive Interventions.
Merle JL; Benbow N; Li DH; Zapata JP; Queiroz A; Zamantakis A; McKay V; Keiser B; Villamar JA; Mustanski B; Smith JD
AIDS Behav; 2024 Jul; 28(7):2321-2339. PubMed ID: 38564136
[TBL] [Abstract][Full Text] [Related]
55. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples.
Ware NC; Wyatt MA; Haberer JE; Baeten JM; Kintu A; Psaros C; Safren S; Tumwesigye E; Celum CL; Bangsberg DR
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):463-8. PubMed ID: 22267018
[TBL] [Abstract][Full Text] [Related]
56. Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for?
Hankins CA
Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):167-70. PubMed ID: 24552641
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of a pre-exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens.
Ramautarsing RA; Meksena R; Sungsing T; Chinbunchorn T; Sangprasert T; Fungfoosri O; Meekrua D; Sumalu S; Pasansai T; Bunainso W; Wongsri T; Mainoy N; Colby D; Avery M; Mills S; Vannakit R; Phanuphak P; Phanuphak N
J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25540. PubMed ID: 32602660
[TBL] [Abstract][Full Text] [Related]
58. Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention - 2018 update.
Yen-Hao Chu I; Wen-Wei Ku S; Li CW; Toh HS; Yang CJ; Wu KS; Wu HJ; Chen SS; Kuo JH; Lin HH; Ko NY
J Microbiol Immunol Infect; 2020 Feb; 53(1):1-10. PubMed ID: 31628087
[TBL] [Abstract][Full Text] [Related]
59. Combination adherence strategy to support HIV antiretroviral therapy and pre-exposure prophylaxis adherence during pregnancy and breastfeeding: protocol for a pair of pilot randomised trials.
Saidi F; Mutale W; Freeborn K; Rosenberg NE; Graybill LA; Maman S; Amico KR; Mollan KR; Phanga T; Milala B; Hill LM; Gottwalt AM; Phiri S; Kalua T; Chi BH
BMJ Open; 2021 Jun; 11(6):e046032. PubMed ID: 34193491
[TBL] [Abstract][Full Text] [Related]
60. PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical Trials.
Dimitrov DT; Mâsse BR; Donnell D
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):444-51. PubMed ID: 26990823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
